Results 21 to 30 of about 578 (168)

Safety of 100 µg venom immunotherapy rush protocols in children compared to adults

Allergy, Asthma & Clinical Immunology, 2017
Background: There is a paucity of studies examining the safety of venom immunotherapy (VIT) in children. We aimed to assess the incidence of anaphylactic side effects during rush VIT in a cohort of pediatric patients and adult controls.
Andreas Kerstan, Christine Hosp, Hosp, Christine, Kerstan, Andreas, Stoevesandt, Johanna, Axel Trautmann, Trautmann, Axel, Johanna Stoevesandt   +7 more
core   +2 more sources

Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial [PDF]

, 2023
93103Background: Non-sedating H1-antihistamines (nsAH) are the most commonly used treatment for chronic spontaneous urticaria (CSU). Many patients use them as on-demand (OD) therapy rather than a maintenance treatment.
Weller, Karsten, Brehler, Randolf B.S., Jakob, Thilo, Groffik, Adriane, Müller, Sabine, Staubach, Petra, Labrador-Horrillo, Moisés, Maurer, Marcus, Ferrer, Marta, Gimenéz-Arnau, Ana María, Baron, J. M., Grundmann, Sonja Alexandra, Wurpts, Gerda, Metz, M.   +13 more
core   +3 more sources

Algorithms of Patient Selection for Allergen Immunotherapy. [PDF]

Allergy
Allergy, Volume 81, Issue 6, Page 2225-2229, June 2026.
Zieglmayer UP, Arasi S, Eiwegger T, Jakob T, Klimek L, Ollert M.   +5 more
europepmc   +2 more sources

Steady steps to desensitization: Low-increment OIT for pediatric wheat allergy. [PDF]

Pediatr Allergy Immunol
Pediatric Allergy and Immunology, Volume 37, Issue 7, July 2026.
Kitsioulis NA, Xepapadaki P, Manousakis E, Taka S, Papadopoulos NG.   +4 more
europepmc   +2 more sources

Real-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients

Indian Journal of Dermatology, 2021
Introduction: Second-generation H1-antihistamines (SGAHs) are the mainstay of treatment of chronic spontaneous urticaria (CSU). Bilastine, newer non-sedating SGAHs, was recently introduced in India after the approval of the Drugs Controller General of ...
Abhishek De, Kiran Godse, Dhiraj Dhoot, Aarti Sarda   +3 more
doaj   +1 more source

Remibrutinib as a Therapeutic Option for Solar Urticaria [PDF]

Photodermatol Photoimmunol Photomed
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Mijares J, Bhagwat M, Gonzalez J, Ramachandran V.   +3 more
europepmc   +2 more sources

Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial [PDF]

, 2023
Background: Non-sedating H1-antihistamines (nsAH) are the most commonly used treatment for chronic spontaneous urticaria (CSU). Many patients use them as on-demand (OD) therapy rather than a maintenance treatment.
Weller, Karsten, Baron, Jens, Grundmann, Sonja, Jakob, Thilo, Groffik, Adriane, Müller, Sabine, Staubach, Petra, Labrador‐Horrillo, Moisés, Gimenez‐Arnau, Ana Maria, Metz, Martin, Maurer, Marcus, Ferrer, Marta, Brehler, Randolf, Wurpts, Gerda   +13 more
core   +1 more source

Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome

Dermatology Practical & Conceptual, 2022
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo, Sara Cazzolla, Francesca Pampaloni, Mauro Alaibac   +3 more
doaj   +1 more source

Efficacy of autologous serum therapy in ASST positive and ASST negative patients in chronic urticaria in a tertiary care centre

Dermatology Reports, 2022
Background: Autologous Serum Therapy (AST) has been a recent therapeutic choice for a variety of chronic diseases such as allergic, inflammatory, infectious, and autoimmune disorders, however evidence were not convincing the beneficial effects of ...
Raghavendra KR, Bangaru H
doaj   +1 more source

H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects--a retrospective survey study. [PDF]

PLoS ONE, 2011
BACKGROUND: The guidelines recommend that first line treatment of chronic spontaneous urticaria should be second generation non-sedating H(1)-antihistamines with a positive recommendation against the use of old sedating first generation antihistamines ...
Karsten Weller, Claudia Ziege, Petra Staubach, Knut Brockow, Frank Siebenhaar, Karoline Krause, Sabine Altrichter, Martin K Church, Marcus Maurer   +8 more
doaj   +1 more source